Streetbeat News

Stock Prices

V

The article provides a comprehensive comparison of Visa (NYSE:V) with its competitors in the Financial Services industry, focusing on key financial metrics. Visa shows potential for growth with a lower P/E ratio than the industry average, but its high P/B and P/S ratios suggest it may be overvalued. Visa's ROE, EBITDA, and gross profit indicate strong profitability and operational efficiency, though its revenue growth lags behind the industry average.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

ABCB

In the past three months, 5 analysts have rated Ameris Bancorp (NYSE:ABCB) with a mix of bullish and somewhat bullish sentiments. Analysts have set a 12-month average price target of $69.4, reflecting a 17.23% increase from the previous target. Recent analyst actions include raised ratings and price targets, indicating positive sentiment towards Ameris's financial performance, which includes strong revenue growth, net margin, and efficient debt management.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

CACI

CACI International (NYSE:CACI) has significantly outperformed the market over the past 15 years, with an average annual return of 16.71%. A $100 investment in CACI 15 years ago would now be worth $1,039.18, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

DELL

Dell Technologies (NYSE:DELL) has significantly outperformed the market over the past 5 years, with an annualized return of 34.53%. A $1000 investment in DELL 5 years ago would now be worth $4,345.25. This highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

LLY

Eli Lilly (NYSE:LLY) is analyzed against its competitors in the Pharmaceuticals industry. The company shows high valuation metrics (PE, PB, PS ratios) compared to industry averages, suggesting potential overvaluation. However, its high ROE and revenue growth indicate strong performance. Concerns arise from lower EBITDA and gross profit levels, which may affect operational efficiency and profitability.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

ETHUSD

Ethereum's price has risen by 4.78% in the last 24 hours, continuing a positive trend with a 7% gain over the past week. Trading volume increased by 96%, while circulating supply slightly decreased. Ethereum's market cap is ranked #2 at $306.76 billion.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 3:00 pm

RR

Richtech Robotics Inc. (NASDAQ:RR) shares experienced volatility after launching an AI-powered beverage service robot, Scorpion, and announcing a distributor agreement with Park 34 Liquor Store Inc. Despite an initial rise, shares fell 12.3% on Friday.

Portfolio Pulse from Erica Kollmann

September 20, 2024 | 2:59 pm

CEG

FDX

SPY

VIX

The article discusses the potential market volatility following September's triple witching, where significant options contracts expire, potentially leading to unusual market activity. Historical data suggests a challenging week ahead for traders, with the S&P 500 often experiencing declines post-witching. The Volatility Index (VIX) is currently low, presenting a potential opportunity for options traders. Goldman Sachs recommends hedging with VIX calls. The article also lists top gainers and laggards in the S&P 500 after Friday's market open.

Portfolio Pulse from Piero Cingari

September 20, 2024 | 2:51 pm

CHWY

Chewy Inc (CHWY) shares fell 4.38% to $29.74 after announcing a public offering of 16.67 million shares by its largest shareholder, Buddy Chester Sub LLC, at $30 per share. Chewy will repurchase $300 million of its Class A stock from the seller, separate from its existing $500 million repurchase program. The offering is expected to close by September 23.

Portfolio Pulse from Henry Khederian

September 20, 2024 | 2:51 pm

MRK

MRNA

MYNZ

PFE

Pfizer presented positive trial data for its experimental drug ponsegromab, aimed at treating cancer cachexia, at the European Society for Medical Oncology 2024 Congress. The drug showed promising results in improving weight and quality of life for patients. Pfizer plans to start late-stage trials in 2025. Moderna and Merck are also advancing in cancer treatment with their experimental cancer vaccine and immunotherapy drug. Mainz Biomed is working on early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

September 20, 2024 | 2:48 pm